AlloVir's RSV Therapy Is Underappreciated Gem, BofA Comments On Future Potential

AlloVir’s RSV Therapy Is Underappreciated Gem, BofA Comments On Future Potential

August 19, 2023

in Stocks

Reading Time: 1 min read

B of A Securities analyst Jason Zemansky initiated coverage on AlloVir Inc (NASDAQ:ALVR) with a Buy rating and announced a price target of $17.

AlloVir is a clinical-stage biotech advancing cell therapies for prevention/ treatment of viruses in immunocompromised patients.

Support authors and subscribe to content

This is premium stuff. Subscribe to read the entire article.

Gain access to all our Premium contents.
More than 100+ articles.

Subscribe Now

Buy Article

Unlock this article and gain permanent access to read it.

Unlock Now

AlloVir’s RSV Therapy Is Underappreciated Gem, BofA Comments On Future Potential

Related Articles

Chinese fintechs slide, while Robinhood, Upstart jump: week’s financials wrap

U.S. is said to expect Israel to strike Iranian military, energy sites (Commodity:CL1:COM)

Trending stocks in another record week for Wall Street

Bitcoin Takes Another Shot at $63.5K as China’s Vague Fiscal Stimulus Deters Capital Shift | Currency News | Financial and Business News

Key deals this week: Arcadium Lithium, Comstock, LendingClub, Chevron and more

KKR bid for Fuji Soft bettered by Bain (NYSE:KKR)

If a Body Part Can Wear AI, Meta’s Likely Tried to Develop It, CTO Says

How AI Is Changing Business at Telecom Giants

How excessive Fedspeak undermines transparency, clarity in Fed’s communication

Navigate Site

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?

AlloVir’s RSV Therapy Is Underappreciated Gem, BofA Comments On Future Potential

Support authors and subscribe to content

Subscribe

Buy Article

Related Articles

Navigate Site

Follow Us

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?